财中社12月20日电白云山(600332/00874)发布关于子公司《药品生产许可证》变更的公告。公告指出,子公司奇星药业近日获得广东省药品监督管理局核准签发的《药品生产许可证》,允许其委托白云山制药总厂生产复方余甘子利咽含片,许可证有效期至2025年9月21日。此次变更涉及的委托生产地址包括广州市番禺区南村镇七星岗及广东省揭西县环城东路36号,委托生产的有效期为3年。公告还提到,此次委托生产...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.